Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Publication number: 20200143906
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health & Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • Publication number: 20200140465
    Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 7, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
  • Publication number: 20200140451
    Abstract: Disclosed is a compound of formula (I) in which a, R1-R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Fundacio Institut Catala D'Investigacio Quimica, University of Delaware, University of Leeds, Universitat Rovira I Virgili
    Inventors: John A. Beutler, Antonio Echavarren, William Chain, David Beech, Zhenhua Wu, Jean-Simon Suppo, Fernando Bravo, Hussein Rubaiy
  • Patent number: 10640571
    Abstract: Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 5, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Mingqian Feng, Dimiter S. Dimitrov, Wei Gao
  • Publication number: 20200129555
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a HLA-A3 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 30, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kenichi Hanada, James C. Yang
  • Patent number: 10633447
    Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 28, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Tianlei Ying
  • Patent number: 10632185
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 28, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Publication number: 20200121790
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicant: The United States of America, as represented by the Secretary Department of Health and Human Service
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Patent number: 10627340
    Abstract: Imaging systems and methods using fluorescent nanodiamonds are disclosed. The imaging systems and methods including applying a time-varying magnetic field to a specimen containing fluorescent nanodiamonds and comparing the fluorescence obtained with different magnetic fields to provide an image of the specimen.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 21, 2020
    Assignees: BIKANTA CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ambika Bumb, Keir Cajal Neuman
  • Publication number: 20200109109
    Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.
    Type: Application
    Filed: April 5, 2018
    Publication date: April 9, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, GLG Pharma, LLC, MRIGlobal
    Inventors: Robert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta
  • Patent number: 10613176
    Abstract: An approach is presented to recontruct image data for an object using a partial set of magnetic resonance (MR) measurements. A subset of data points in a data space representing an object are selected (e.g. through random sampling) for MR data acquisition. Partial MR data corresponding to the subset of data points is received and used for image reconstruction. The overall speed of image reconstruction can be reduced dramatically by relying on acquisition of data for the subset of data points rather than for all data points in the data space representing the object. Compressive sensing type arguments are used to fill in missing measurements, using a priori knowledge of the structure of the data. A compressed data matrix can be recovered from measurements that form a tight frame. It can be established that these measurements satisfy the restricted isometry property (RIP). The zeroth-order regularization minimization problem can then be solved, for example, using a 2D ILT approach.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 7, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Peter J. Basser, Ruiliang Bai, Alexander Cloninger, Wojciech Czaja
  • Patent number: 10611815
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • Patent number: 10611816
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 7, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Publication number: 20200102567
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: April 2, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200105364
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • Publication number: 20200102383
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 2, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
  • Publication number: 20200102604
    Abstract: Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.
    Type: Application
    Filed: May 4, 2018
    Publication date: April 2, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Giovanna Tosato, Hidetaka Ohnuki
  • Patent number: 10604499
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 31, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Patent number: 10603021
    Abstract: Disclosed herein are devices and methods for closing a hole in the wall of a cardiovascular structure from the inside using a self-assembling closure device. The closure device can be delivered to the subject hole from the inside of the cardiovascular chamber using a transcatheter approach. Disclosed techniques involve deploying the closure device from the delivery device such that an endo-cameral portion of the closure device self-expands first to cover the hole from the inside, and then extra-cameral arms of the device are released to self-deploy against the outside of the wall by withdrawal of a retaining element, such as a guidewire, to secure the closure device to the wall.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 31, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Toby Rogers, Merdim Sonmez, Ozgur Kocaturk, Robert J. Lederman
  • Patent number: 10604583
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: March 31, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.
    Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha